Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Giulia Mazzaschi, Roberta Minari, Alessandra Zecca, +15

Lung Cancer

Cancer ImmunosurveillanceAutoimmune DiseaseAllergySoluble Pd-l1Circulating Cd8+pd-1+ +9

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells

Mara Bonelli, Graziana Digiacomo, Claudia Fumarola, +16

Neoplasia

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Daniele Cretella, Andrea Ravelli, Claudia Fumarola, +8

Journal of Experimental & Clinical Cancer Research

Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis

Roberta Alfieri, Andrea Cavazzoni, Pier Giorgio Petronini, +4

The Journal of Physiology

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Silvia La Monica, Daniele Cretella, Mara Bonelli, +10

Journal of Experimental & Clinical Cancer Research

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

Andrea Cavazzoni, Mara Bonelli, Claudia Fumarola, +13

Cancer Letters

Breast OncologyMedicineBreast CancerAnti-cancer AgentTumor Suppressor +5

5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity

Caterina Carmi, Andrea Cavazzoni, Valentina Zuliani, +6

Bioorganic & Medicinal Chemistry Letters

Molecular PharmacologyMedicinal ChemistryMedicineNew Egfr InhibitorsPharmacotherapy +4

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells

Daniele Cretella, Claudia Fumarola, Mara Bonelli, +7

Scientific Reports

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

Silvia La Monica, Maricla Galetti, Roberta Alfieri, +11

Biochemical Pharmacology

Gefitinib SensitivityMedicineImmune Checkpoint InhibitorCancer BiologyCancer Treatment +5

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

Andrea Cavazzoni, Roberta Alfieri, Caterina Carmi, +9

Molecular Cancer Therapeutics